[2] Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology, 21(1), 169.https://doi.org/10.1186/s129...
[28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs." Diabetes Care 45.2 (2022): 372-380...
[27] Luli, Alex, et al. "Barriers to Obtaining GLP-1 Receptor Agonists and SGLT2 Inhibitors in a Free Clinic Population With Type 2 Diabetes and Cardiovascular Disease." Journal of Contemporary Pharmacy Practice 70.1 (2023): 9-13. [28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2...
“利拉鲁肽”(liraglutide)是GLP-1的受体激动剂，先说它的原理。胰高血糖素样肽-1（GLP-1）是肠道...
血脂异常不良事件在Survodutide各治疗组中共发生2例,分别出现在2.4 mg和3.6 mg剂量组,而安慰剂组则记录到1例,这些事件均表现为轻度且没有导致受试者治疗中断。 低血压不良事件在Survodutide各治疗组中共5例报告(1例为合并基础高血...
[8] Merck steps into NASH space with early data for its GLP-1/glucagon receptor co-agonist. Retrieved June 14, 2023, from https://endpts.com/merck-steps-into-liver-disease-space-with-early-data-for-its-glp-1-glucagon-receptor-co-agonist/ ...
BACKGROUND: We assessed the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of...
[4] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial,Retrieved August 10, 2023 from https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301 ...
大量流行病学研究结果证实,超重和肥胖是诱发血脂异常、非酒精性脂肪肝 (Nonalcoholic fatty liver disease, NAFLD)、代谢综合征 (Metabolic syndrome ,MetS )、心血管疾病 (Cardiovascular disease,CVD)、2型糖尿病 (type 2 diabetes mellitus,T2DM)、慢性肾病、多囊卵巢综合征(Polycystic ovary syndrome,PCOS)、睡眠...
12月15日,知名学术期刊《科学》公布胰高血糖素样肽-1(GLP-1)激动剂获选为2023年度科学突破(Science’s 2023 Breakthrough of the Year),这标志着在对抗肥胖症及其相关并发症的长期斗争中的重要里程碑。这项科学成就不仅在肥胖症治疗领域产生了深远影响,而且...